This story first appeared in DNA Money edition on Wednesday, July 25, 2012.
Lupin Ltd, the third largest Indian pharma company by sales, is upping the ante on expansion. The company has lined up a significant capital expenditure in the current fiscal across various therapeutic areas and on expansion of existing units, a senior company official said.
Ramesh Swaminathan, president – finance & planning and CFO, told DNA Money, “We will invest around $100-120 million (Rs550 crore) in capex this fiscal.” The company will fund the expansion with internal funds.
It has also chalked out aggressive product launches with a robust pipeline across global markets, particularly the US, Europe and Japan.
“We’ll have more than 20-25 products in America alone. In Japan we are looking at close to 20 products over three years and 30-40 products in India on an annual basis,” said Swaminathan on the sidelines of the company’s annual general meeting on Tuesday.
Lupin’s US sales jumped 40% in dollar terms in the April to June 2012 quarter.
In rupee terms, the company’s net profit rose 33% to Rs280.4 crore year on year on higher double-digit sales growth across the US, Japan and India. Net sales rose 44% to Rs2,219.2 crore.
Kamal K Sharma, managing director, Lupin, said, “Strong operating performance, aided by product launches and exceptional growth across US, India, Japan and South Africa, have helped us deliver yet another quarter of sustained growth.”
Highlights of the quarter included a decline in material and personnel costs 3% and 0.6%, respectively though manufacturing and other expenses increased 2.2% year on year (yoy).
Swaminathan said manufacturing and other expenses increased because of higher research & development spend of close to 1%, in addition to lumpiness in sales and promotional expenses.
The company’s US and Europe formulation sales contributed 38% to its consolidated revenues for the June quarter as they grew 60% to Rs841.3 crore yoy.
Its interest and finance expenses rose 74.4% to Rs10.1 crore in the reporting quarter, which Swaminathan said was largely because the company had made an acquisition in Japan. In November, Lupin, through its subsidiary Kyowa Pharmaceutical, had bought Japanese firm I’rom Holdings Co.
Lupin Ltd, the third largest Indian pharma company by sales, is upping the ante on expansion. The company has lined up a significant capital expenditure in the current fiscal across various therapeutic areas and on expansion of existing units, a senior company official said.
Ramesh Swaminathan, president – finance & planning and CFO, told DNA Money, “We will invest around $100-120 million (Rs550 crore) in capex this fiscal.” The company will fund the expansion with internal funds.
It has also chalked out aggressive product launches with a robust pipeline across global markets, particularly the US, Europe and Japan.
“We’ll have more than 20-25 products in America alone. In Japan we are looking at close to 20 products over three years and 30-40 products in India on an annual basis,” said Swaminathan on the sidelines of the company’s annual general meeting on Tuesday.
Lupin’s US sales jumped 40% in dollar terms in the April to June 2012 quarter.
In rupee terms, the company’s net profit rose 33% to Rs280.4 crore year on year on higher double-digit sales growth across the US, Japan and India. Net sales rose 44% to Rs2,219.2 crore.
Kamal K Sharma, managing director, Lupin, said, “Strong operating performance, aided by product launches and exceptional growth across US, India, Japan and South Africa, have helped us deliver yet another quarter of sustained growth.”
Highlights of the quarter included a decline in material and personnel costs 3% and 0.6%, respectively though manufacturing and other expenses increased 2.2% year on year (yoy).
Swaminathan said manufacturing and other expenses increased because of higher research & development spend of close to 1%, in addition to lumpiness in sales and promotional expenses.
The company’s US and Europe formulation sales contributed 38% to its consolidated revenues for the June quarter as they grew 60% to Rs841.3 crore yoy.
Its interest and finance expenses rose 74.4% to Rs10.1 crore in the reporting quarter, which Swaminathan said was largely because the company had made an acquisition in Japan. In November, Lupin, through its subsidiary Kyowa Pharmaceutical, had bought Japanese firm I’rom Holdings Co.
No comments:
Post a Comment